Gyre Therapeutics is trading at $4.32, down 5.16%, with no identified company-specific announcement explaining the decline. - On November 2, 2026, a market roundup likewise found no confirmed company announcement behind the stock’s move. - Biotech shares were lower, while broad U.S. indices were higher; neither sector nor overall-market conditions clearly explains the decline, and its cause remains uncertain.